Kamada Ltd.

NasdaqGS:KMDA Stock Report

Market Cap: US$411.7m

Kamada Dividends and Buybacks

Dividend criteria checks 3/6

Kamada is a dividend paying company with a current yield of 3.5% that is well covered by earnings.

Key information

3.5%

Dividend yield

-0.001%

Buyback Yield

Total Shareholder Yield3.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ratio71%

Recent dividend and buyback updates

Recent updates

Seeking Alpha • Jun 02

Kamada: Undervalued, Yet Execution Risks Keep It A Hold

Summary Kamada Ltd. maintains solid demand and profitability, but near-term margin pressures and execution risks justify a hold rating. FDA approval of the in-house RFFIT lab removes a key operational bottleneck, supporting vertical integration and future growth in the rabies franchise. 1Q26 results showed stable revenues ($45.2M, +3% YoY) and a robust 26% EBITDA margin, offset by gross margin compression and shipment timing effects. KMDA trades at a discount to the sector on FWD EV/EBITDA (7.4x vs. 11.6x), but the market discounts margin sustainability and execution risks despite strong forward growth prospects. Read the full article on Seeking Alpha
Seeking Alpha • Oct 19

Kamada secures $22M extension of Canadian supply tender

Kamada (NASDAQ:KMDA) was awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG® and WINRHO® SDF, for an additional three years for an approximate total value of $22M. The award secures the ongoing sales of those products in the Canadian market. The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration were acquired by Kamada in November 2021. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec. The supply extension secures ongoing sales of approximately $7.5M per year for 2023-2025, with an option to extend for up to additional two years. Commercial manufacturing of CYTOGAM at Kamada’s Israeli manufacturing plant is expected to be initiated during 2023.
Seeking Alpha • Aug 16

Kamada Q2 2022 Earnings Preview

Kamada (NASDAQ:KMDA) is scheduled to announce Q2 earnings results on Wednesday, August 17th, before market open. The consensus EPS Estimate is -$0.02 (-200.0% Y/Y) and the consensus Revenue Estimate is $23.69M (-2.1% Y/Y). Over the last 1 year, KMDA has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Too early to tell whether KMDA's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if KMDA's dividend payments are increasing as they only just started paying a dividend.

Dividend Yield vs Market

Kamada Dividend Yield vs Market
How does KMDA dividend yield compare to the market?
SegmentDividend Yield
Company (KMDA)3.5%
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (KMDA) (up to 3 years)n/a

Notable Dividend: KMDA's dividend (3.5%) is higher than the bottom 25% of dividend payers in the US market (1.37%).

High Dividend: KMDA's dividend (3.5%) is low compared to the top 25% of dividend payers in the US market (4.19%).

Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (71.5%), KMDA's dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: At its current cash payout ratio (88.1%), KMDA's dividend payments are covered by cash flows.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 00:36
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kamada Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Andrew FeinH.C. Wainwright & Co.
Anthony PetroneJefferies LLC